Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Appointed CFO
Quarterly results
Auditor change
Eledon Pharmaceuticals, Inc. (NVUS) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 8-K Quarterly results
08/10/2023 8-K Quarterly results
Docs: "Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results Ninth patient dosed in ongoing Phase 1b trial evaluating tegoprubart in patients undergoing kidney transplantation; updated clinical data expected in the fourth quarter Raised up to $185 million, including $35 million upfront, from leading investors Successfully completed a non-human primate study for subcutaneous tegoprubart formulation"
05/11/2023 8-K Quarterly results
Docs: "Eledon Pharmaceuticals Reports First Quarter 2023 Operating and Financial Results Reported open-label data from ongoing Phase 1b trial of tegoprubart in kidney transplantation demonstrating mean eGFRs from 3 participants above 70 mL/min/1.73m2 at measured timepoints Completed financing of up to $185 million, with $35 million upfront, to fund the Company through the Phase 2 BESTOW kidney transplant trial, subject to achieving specific milestones Conference call today at 4:30 p.m. ET"
05/01/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Departure of Directors or Certain Office...
Docs: "PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK ELEDON PHARMACEUTICALS, INC. Warrant Shares: _______ Issue Date:______, 20__ Initial Exercise Date: _______, 20__ THIS PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above and until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from Eledon Pharmaceuticals, Inc., a Delaware corporation , up to ______ shares of the Company’s common stock, par value $0.001 per share . The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Se...",
"TRANCHE A WARRANT TO PURCHASE COMMON STOCK",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of April 28, 2023, between Eledon Pharmaceuticals, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an exemption from the registration requirements contained in Section 4 of the Securities Act of 1933, as amended , and/or Rule 506 promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consid...",
"REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement is made and entered into as of April 28, 2023, by and between Eledon Pharmaceuticals, Inc., a Delaware corporation , and each of the several purchasers signatory hereto . This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and each Purchaser . The Company and each Purchaser hereby agrees as follows: 1. Definitions. Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the Purchase Agreement. As used in this Agreement, the following terms shall have the following meanings: “Advice” shall have the meaning set forth in Section 6. “Effectiveness Date&#x201...",
"Eledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials $35 million in upfront financing with the potential to receive additional aggregate financing up to $105 million, subject to achieving clinical development milestones, plus up to $45 million upon exercise of warrants Led by BVF Partners LP and Armistice Capital, with participation from new investor Sanofi Aggregate financing expected to be sufficient to fund Company through the completion of the Phase 2 BESTOW trial evaluating tegoprubart for the prevention of rejection in patients receiving a kidney transplant"
01/09/2023 8-K Quarterly results
11/14/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
06/22/2022 8-K Quarterly results
05/31/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/24/2022 8-K Quarterly results
Docs: "Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Operating and Financial Results Topline data from Phase 2a trial of tegoprubart in ALS expected in 2Q 2022"
01/13/2022 8-K Unregistered Sales of Equity Securities, Financial Statements and Exhibits  Interactive Data
Docs: "Series X1 Exchange Agreement, by and among Eledon Pharmaceuticals, Inc. and the Stockholders named therein"
11/12/2021 8-K Quarterly results
Docs: "Eledon Pharmaceuticals Reports Third Quarter 2021 Operating and Financial Results Nearing full enrollment in ALS Phase 2 Study; topline data expected 1H 2022"
08/12/2021 8-K Quarterly results
08/02/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/02/2021 8-K Appointed a new director
06/16/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
04/26/2021 8-K Other Events, Financial Statements and Exhibits
Docs: "Eledon Pharmaceuticals Announces Update on Development Strategy for AT-1501 in Renal Transplantation"
03/15/2021 8-K Quarterly results
01/07/2021 8-K Quarterly results
01/05/2021 8-K Quarterly results
12/22/2020 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
12/10/2020 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
11/20/2020 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "Amended and Restated Bylaws of the Company, effective as of November 20, 2020"
10/06/2020 8-K Quarterly results
09/15/2020 8-K Entered into consulting agreement, Appointed a new director
Docs: "Agreement and Plan of Merger, by and among Novus Therapeutics, Inc., Nautilus Merger Sub 1, Inc., Nautilus Merger Sub 2, LLC and Anelixis Therapeutics, Inc",
"Certificate of Designations of Series X1 Convertible Preferred Stock",
"Stock Purchase Agreement, by and among Novus Therapeutics, Inc. and each purchaser identified on Annex A thereto",
"Form of Registration Rights Agreement, by and among Novus Therapeutics, Inc. and certain purchasers",
"Novus Therapeutics Announces Acquisition of Anelixis Therapeutics"
09/04/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report September 4, 2020 Novus Therapeutics, Inc. Delaware 001-36620 20-1000967 19900 MacArthur Blvd., Suite 550 Irvine, California 92612 238-8090 Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the E..."
06/17/2020 8-K Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm...
05/15/2020 8-K Quarterly results
Docs: "Novus Therapeutics Reports First Quarter 2020 Financial Results"
05/13/2020 8-K Quarterly results
04/23/2020 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
03/17/2020 8-K Quarterly results
Docs: "Novus Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results Data from the fully enrolled phase 2a efficacy study in infants and children with acute otitis media to be announced by early June 2020"
02/19/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy